2024/07/11 08:10:48 | |
---|---|
Price | |
0.7795 EUR | |
Difference | 2.70% (0.02) |
ISIN | NL0010391025 |
Symbol | PHARM |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 542 EUR |
Benchmark | AMSTERDAM EXCHANGES INDEX |
Bid (Bid size) | 0.7985 EUR (1,880) |
Ask (Ask size) | 0.811 EUR (1,880) |
Open | 0.7795 EUR |
High | 0.7795 EUR |
Low | 0.7795 EUR |
Close (prev. day) | 0.759 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2024/05/29 |
![]() |
Global Equity Ratings |
![]() |
2024/04/26 |
![]() |
Global Equity Ratings |
![]() |
2024/04/03 |
![]() |
Global Equity Ratings |
![]() |
2024/07/11 08:10:48 | |
---|---|
Price | |
0.7795 EUR | |
Difference | 2.70% (0.02) |
ISIN | NL0010391025 |
Symbol | PHARM |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 542 EUR |
Benchmark | AMSTERDAM EXCHANGES INDEX |
Bid (Bid size) | 0.7985 EUR (1,880) |
Ask (Ask size) | 0.811 EUR (1,880) |
Open | 0.7795 EUR |
High | 0.7795 EUR |
Low | 0.7795 EUR |
Close (prev. day) | 0.759 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -36.27% | -28.73% | -20.61% |
Perf (abs.) | -0.43 | -0.31 | -0.20 |
Beta | 1.24 | 0.80 | 0.79 |
Volatility | 31.90 | 31.33 | 43.77 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.7557 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.7681 EUR (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.9012 EUR (0) |
Ø price 250 days | Ø volume 250 days (pcs.) | 1.0267 EUR (0) |
YTD High | date | 1.2060 EUR (2024/01/11) |
YTD Low | date | 0.7375 EUR (2024/06/20) |
52 Weeks High | date | 1.3040 EUR (2023/09/18) |
52 Weeks Low | date | 0.7375 EUR (2024/06/20) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/07/11 | 16:25 | 0.8045 EUR | 0.03 | 11 |
Stuttgart | 2024/07/11 | 15:26 | 0.798 EUR | 0.00 | 8 |
Munich | 2024/07/11 | 08:16 | 0.7815 EUR | 0.00 | 1 |
London Stock Exchange European Trade Reporting | 2024/07/11 | 17:30 | 0.801 EUR | 0.00 | 2 |
Frankfurt | 2024/07/11 | 08:06 | 0.775 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/07/05 | 17:53 | 0.85 USD | 0.00 | 1 |
Euronext Amsterdam | 2024/07/11 | 17:35 | 0.805 EUR | 3.07 | 1,057 |
Duesseldorf | 2024/07/11 | 08:10 | 0.7795 EUR | 0.00 | 1 |
Berlin | 2024/07/11 | 08:16 | 0.7815 EUR | 0.00 | 1 |
PHARMING GROUP NV |
- - |
Darwinweg 24 - 2333 CR Leiden |
Telefon: +31-71-524-74-00 |
Fax: + |
E-mail: info@pharming.com |
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands. |
Sijmen de Vries | Chairman of Managing Board |
Anurag Relan | Member of Executive Committee |
Jeroen Wakkerman | Member of Executive Committee |
Mireille Sanders | Member of Executive Committee |
Ruud van Outersterp | Member of Executive Committee |
Stephen Toor | Member of Executive Committee |
Richard Peters | Chairman of Supervisory Board |
Jabine T. M. van der Meijs | Member of Supervisory Board |
Mark Pykett | Member of Supervisory Board |
Barbara Yanni | Member of Supervisory Board |
Deborah Jorn | Member of Supervisory Board |
Leonard Kruimer | Member of Supervisory Board |
Steven Baert | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer